Impact

California Pacific CURRENTS: The online journal of CPMC Research Institute

Kat Rains was treated for aggressive cancer at CPMC.

Kat Rains was diagnosed with breast cancer at 28 weeks of pregnancy. After delivering her daughter Alice, Kat underwent treatment for her aggressive cancer at CPMC.

Impact

  • Through the institute’s translational research focus, our investigators are changing clinical practice and transforming early-stage ideas into new diagnostics and therapeutics including companion diagnostics, novel methods to detect and treat ischemic stroke, and more precise, combination and targeted therapies for aggressive cancers.
  • Each year, CPMCRI investigators initiate hundreds of clinical study protocols across Northern California in amyotrophic lateral sclerosis (ALS) and other neurodegenerative conditions, breast cancer, melanoma, chronic pain, obstetrics and gynecology, stroke, and orthopedic surgery. Our clinical trials and research offer patients access to the latest therapies for challenging illnesses, and we align industry sponsors and clinicians to benefit patients.
  • Outcomes and health services research at CPMCRI is transforming the delivery of health care at CPMC and among Sutter Health affiliates—reducing postoperative emergency room visits and readmissions, decreasing unnecessary procedures including C-sections, and lessening overall hospital costs.
  • Large multi-center studies—in women's health, aging, cognitive function, cardiovascular disease, breast cancer prevention, osteoporosis, and arthritis—initiated at CPMCRI in partnership with the San Francisco Coordinating Center have significantly advanced research into common, chronic illnesses:
    • Our studies on longevity have accumulated the largest, richest datasets about aging in the U.S.
    • Large-cohort studies in osteoporosis and breast cancer have yielded some of the most powerful datasets in the U.S. to help improve the treatment of these illnesses.
  • Biorepositories at CPMCRI and among other Sutter Health affiliates are being used to help predict risk of breast cancer, pinpoint early molecular events underlying glioblastoma, identify aggressive melanomas before onset of disease, pioneer new vaccines for liver diseases, and prevent organ rejection in kidney transplant patients.

Learn more about our research and recent examples of the impact of our work on patient care. Review our 2015 annual report.